25 Feb 2021 --- Ferring, Rebiotix and MyBiotics have entered into a multi-year collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis (BV). BV is a common vaginal infection among women of reproductive age that has been linked to an increased risk of miscarriage and complications to pregnancy and fertility.
